Feed aggregator

SQRIL expands into Africa with stablecoin-to-fiat QR payments

Top Stories - Mon, 04/20/2026 - 01:58

Why Some Investors Are Buying Gold-Backed Cryptocurrency Instead of Bitcoin

Top Stories - Mon, 04/20/2026 - 01:57

Vanguard says most people donate to charity the wrong way — these 3 strategies can save you thousands in taxes

Top Stories - Mon, 04/20/2026 - 01:45

Is Visa (V) The Best Long-Term Stock to Buy Now?

Top Stories - Mon, 04/20/2026 - 01:42

Is Mastercard (MA) The Best Stock to Buy According to Motley Fool Asset Management?

Top Stories - Mon, 04/20/2026 - 01:41

Apple withholds data in India antitrust case, watchdog sets final hearing

Top Stories - Mon, 04/20/2026 - 01:38

Apple withholds data in India antitrust case, watchdog sets final hearing

Top Stories - Mon, 04/20/2026 - 01:38

Spyre (SYRE) Climbs 42% as Treatment Candidate Poses ‘Best-in-Class’ Potential

Top Stories - Sun, 04/19/2026 - 16:50

National Australia Bank flags $503 million impairment hit on Mideast volatility

Top Stories - Sun, 04/19/2026 - 16:48

Travere Therapeutics (TVTX) Climbs 40.8% on Filspari Approval

Top Stories - Sun, 04/19/2026 - 16:47

Mizuho Cuts PT on ADMA Biologics Inc. (ADMA) to $24 From $30

Top Stories - Sun, 04/19/2026 - 16:12

Wells Fargo Cuts PT on Nurix Therapeutics (NRIX) to $28 From $29

Top Stories - Sun, 04/19/2026 - 16:12

JonesResearch Initiates Coverage of Relay Therapeutics (RLAY) With a Hold Rating

Top Stories - Sun, 04/19/2026 - 16:12

Canaccord Initiates Coverage of Biohaven Ltd. (BHVN) With a Buy Rating

Top Stories - Sun, 04/19/2026 - 16:11

H.C. Wainwright Initiates Coverage of Generate Biomedicines (GENB) With a Buy Rating

Top Stories - Sun, 04/19/2026 - 16:11

Why Mesoblast Limited (MESO) is One of the Best Low Priced Biotech Stocks to Invest in

Top Stories - Sun, 04/19/2026 - 16:11

Is Vir Biotechnology (VIR) One of the Best Low Priced Biotech Stocks to Invest In?

Top Stories - Sun, 04/19/2026 - 16:11

Ocular Therapeutix (OCUL) Announces Additional Positive Data From the SOL-1 Phase 3 Superiority Trial of AXPAXLI

Top Stories - Sun, 04/19/2026 - 16:10

Guggenheim Cuts PT on Valneva SE (VALN) to $11 From $13

Top Stories - Sun, 04/19/2026 - 16:10

B. Riley Lifts PT on Theravance Biopharma (TBPH) to $17 From $14

Top Stories - Sun, 04/19/2026 - 16:09
Syndicate content
 
Worldstockexchange® Information Center